In this chapter published in The Guide to Damages in International Arbitration, Gregory Bell, Andrew Tepperman, and Justin Ho provide a brief overview of salient characteristics of the life sciences sector, with a focus on the biopharmaceutical industry, and outline some of the main types of disputes heard in life sciences arbitrations. The authors then discuss some of the aspects of common analyses specific to life sciences that are used to determine damages in these types of disputes.
The chapter begins on p. 16 of the PDF.
Damages in Life Sciences Arbitration is reproduced with permission from Law Business Research Ltd. The Guide to Damages in International Arbitration, 5th edition, John A. Tranor, Editor.
